Tukysa
Tucatinib Plus T-DM1 Improves PFS in Metastatic Breast Cancer
Adding tucatinib (Tukysa, Seagen) to trastuzumab emtansine (Kadcyla, T-DM1, Genentech) improved progression-free ...
FEBRUARY 19, 2024
Tukysa Approved for RAS Wild-Type, HER2-Positive Unresectable or Metastatic Colorectal Cancer
The FDA granted accelerated approval for tucatinib (Tukysa, Seagen) in combination with trastuzumab for adult ...
JANUARY 20, 2023
New TKI May be a Game Changer for Breast Cancer
Advances in therapy have improved overall survival for patients with HER2-positive metastatic breast cancer, but ...
AUGUST 26, 2020
Tukysa Approved in Combination With Chemo for Nonresectable HER2+ Breast Cancer
The FDA approved the tyrosine kinase inhibitor tucatinib (Tukysa, Seattle Genetics) in combination with ...
APRIL 23, 2020
Load more